Stocks in play: Trillium Therapeutics Inc.
Reported financial and operating results for the six months ended June 30, 2018. As of June 30, 2018, Trillium had cash and cash equivalents and marketable securities, and working capital of $64.7 million and $53.4 million, respectively, compared to $81.8 million and $68.9 million, respectively at December 31, 2017. Net loss for the six months ended June 30, 2018 of $20.9 million was lower than the loss of $23.1 million for the six months ended June 30, 2017. Trillium Therapeutics Inc. shares T.TRIL are trading unchanged at $6.34.